Clinical Trial Detail

NCT ID NCT02924402
Title Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Xencor, Inc.
Indications

hairy cell leukemia

B-cell adult acute lymphocytic leukemia

CLL/SLL

B-cell lymphoma

Therapies

XmAb13676

Age Groups: adult senior

No variant requirements are available.